AIM: Whether direct-acting antiviral (DAA) therapy can reduce liver fibrosis and steatosis in patients with chronic hepatitis C virus (HCV) infection remains unclear. We evaluated sequential changes in liver stiffness and steatosis using transient elastography (TE) and the TE-based controlled attenuation parameter (CAP) in patients with HCV who received DAA therapy. PATIENTS AND METHODS: A total of 57 patients with HCV who received DAA therapy and achieved sustained virological response (SVR) were analyzed. Liver stiffness as evaluated with TE, steatosis as evaluated with CAP, and laboratory data were assessed before treatment (baseline), at end of treatment (EOT), 24 weeks after EOT (SVR24), and 48 weeks after EOT (SVR48). RESULTS: Alanine aminotransferase levels, corresponding to the presence of necroinflammatory activity, significantly decreased overall, with significant differences between baseline and EOT, EOT, and SVR24, and baseline and SVR48. However, alanine aminotransferase levels showed no significant changes between SVR24 and SVR48. Median (interquartile range) liver stiffness values at baseline, EOT, SVR24, and SVR48 were 8.3 (5.0-14.8), 7.4 (4.6-14.7), 5.3 (4.1-11.8), and 5.4 (4.0-13.4) kPa, respectively (baseline vs. EOT, P=0.044; EOT vs. SVR24, P=0.011; and SVR24 vs. SVR48, P=0.054). In patients with fatty liver (CAP≥236 dB/m, n=14), CAP values at baseline and SVR48 were 253 (245-278) and 229 (209-249) dB/m, respectively (P=0.020). CONCLUSION: Liver stiffness at SVR24 might reflect liver fibrosis in the patients who received DAA therapy and achieved SVR. In addition, liver steatosis reduces in the same cohort with fatty liver.
AIM: Whether direct-acting antiviral (DAA) therapy can reduce liver fibrosis and steatosis in patients with chronic hepatitis C virus (HCV) infection remains unclear. We evaluated sequential changes in liver stiffness and steatosis using transient elastography (TE) and the TE-based controlled attenuation parameter (CAP) in patients with HCV who received DAA therapy. PATIENTS AND METHODS: A total of 57 patients with HCV who received DAA therapy and achieved sustained virological response (SVR) were analyzed. Liver stiffness as evaluated with TE, steatosis as evaluated with CAP, and laboratory data were assessed before treatment (baseline), at end of treatment (EOT), 24 weeks after EOT (SVR24), and 48 weeks after EOT (SVR48). RESULTS: Alanine aminotransferase levels, corresponding to the presence of necroinflammatory activity, significantly decreased overall, with significant differences between baseline and EOT, EOT, and SVR24, and baseline and SVR48. However, alanine aminotransferase levels showed no significant changes between SVR24 and SVR48. Median (interquartile range) liver stiffness values at baseline, EOT, SVR24, and SVR48 were 8.3 (5.0-14.8), 7.4 (4.6-14.7), 5.3 (4.1-11.8), and 5.4 (4.0-13.4) kPa, respectively (baseline vs. EOT, P=0.044; EOT vs. SVR24, P=0.011; and SVR24 vs. SVR48, P=0.054). In patients with fatty liver (CAP≥236 dB/m, n=14), CAP values at baseline and SVR48 were 253 (245-278) and 229 (209-249) dB/m, respectively (P=0.020). CONCLUSION:Liver stiffness at SVR24 might reflect liver fibrosis in the patients who received DAA therapy and achieved SVR. In addition, liver steatosis reduces in the same cohort with fatty liver.
Authors: Monika Rau; Peter Buggisch; Stefan Mauss; Klaus H W Boeker; Hartwig Klinker; Tobias Müller; Albrecht Stoehr; Jörn M Schattenberg; Andreas Geier Journal: PLoS One Date: 2022-06-16 Impact factor: 3.752
Authors: Tea L Laursen; Thomas D Sandahl; Konstantin Kazankov; Jacob George; Henning Grønbæk Journal: World J Gastroenterol Date: 2020-06-14 Impact factor: 5.742
Authors: Ewa Janczewska; Dorota Zarębska-Michaluk; Hanna Berak; Anna Piekarska; Andrzej Gietka; Dorota Dybowska; Włodzimierz Mazur; Teresa Belica-Wdowik; Witold Dobracki; Magdalena Tudrujek-Zdunek; Zbigniew Deroń; Iwona Buczyńska; Marek Sitko; Agnieszka Czauż-Andrzejuk; Beata Lorenc; Jolanta Białkowska-Warzecha; Jolanta Citko; Łukasz Laurans; Jerzy Jaroszewicz; Łukasz Socha; Olga Tronina; Brygida Adamek; Andrzej Horban; Waldemar Halota; Barbara Baka-Ćwierz; Krzysztof Tomasiewicz; Krzysztof Simon; Aleksander Garlicki; Marta Wawrzynowicz-Syczewska; Robert Flisiak Journal: BMC Infect Dis Date: 2018-11-16 Impact factor: 3.090